July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
iStent Outcomes after Selective Laser Trabeculoplasty
Author Affiliations & Notes
  • Geraldine Slean
    Ophthalmology, CPMC, San Francisco, California, United States
  • Kimberly Tang
    Ophthalmology, CPMC, San Francisco, California, United States
  • Scott So
    Ophthalmology, CPMC, San Francisco, California, United States
  • George Tanaka
    Ophthalmology, CPMC, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Geraldine Slean, None; Kimberly Tang, None; Scott So, None; George Tanaka, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2046. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Geraldine Slean, Kimberly Tang, Scott So, George Tanaka; iStent Outcomes after Selective Laser Trabeculoplasty. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2046.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To compare outcomes of iStent with phacoemulsification after selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) for up to 12 months of follow-up.

Methods : Outcome variables included intraocular pressure (IOP) and anti-glaucoma medications used, which were analyzed with Student’s t-tests. Patients were included if maximum preoperative IOP was ≥21 and at least one preoperative anti-glaucoma medication was used.

Results : 50 eyes in 43 patients were included in this study with 18 patients having undergone SLT prior to iStent placement. The study included 27 POAG eyes and 23 PXG eyes with 9 patients having undergone SLT in each subgroup. Mean preoperative IOP was 17.56 ± 4.82 and mean preoperative medical usage was 1.92 ± 1.03 drops. After iStent placement, mean IOP was significantly reduced at postoperative months 3, 6, 9, and 12. After iStent placement, mean medication usage was also significantly reduced at all postoperative visits. No differences in IOP or medication usage were noted both preoperatively and postoperatively in eyes that had previously received treatment with SLT versus those that had not.

Conclusions : iStent placement alongside phacoemulsification did demonstrate significant reductions in postoperative IOP and medication usage for up to 12 months of follow-up. Prior SLT did not impact iStent outcomes in terms of intraocular pressure or medication usage.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.